Retroperitoneal Fibrosis (Ormond's Disease)

1. Executive Overview: Understanding Retroperitoneal Fibrosis (Ormond’s Disease)

Retroperitoneal fibrosis (RPF), historically termed Ormond’s Disease, is a rare, complex fibro-inflammatory disorder characterized by the development of a dense, fibrous tissue mass in the retroperitoneal space. This mass typically envelops the abdominal aorta, iliac arteries, and, most critically, the ureters.

From a nephrological perspective, the primary clinical concern is the obstructive uropathy that arises when the fibrotic plaque compresses the ureters. This leads to hydronephrosis, progressive decline in the estimated glomerular filtration rate (eGFR), and the potential for rapid progression to chronic kidney disease (CKD) or acute kidney injury (AKI). While RPF can be idiopathic (occurring in two-thirds of cases), it is frequently associated with autoimmune systemic conditions, malignancies, or drug-induced fibrotic reactions. Effective management requires a multidisciplinary approach involving nephrologists, urologists, and rheumatologists to preserve renal function and mitigate systemic inflammation.

2. Pathophysiology, Etiology, and Risk Factors

The pathogenesis of RPF involves an immune-mediated inflammatory process that transitions into excessive collagen deposition.

Pathophysiological Mechanisms

• Chronic Periaortitis: The fibrotic process often initiates around the infrarenal abdominal aorta, suggesting an underlying response to oxidized lipoproteins or neoantigens in the aortic wall.
• Ureteral Compression: As the fibrous plaque expands, it creates extrinsic compression of the ureters, leading to post-renal obstruction.
• Tubulointerstitial Damage: Persistent obstruction leads to increased hydrostatic pressure in the renal pelvis, resulting in tubular atrophy, interstitial fibrosis, and eventual glomerular sclerosis.

Etiological Classifications

3. Signs, Symptoms, and Clinical Presentation

The clinical presentation of RPF is often insidious, making early detection a diagnostic challenge. Symptoms are primarily driven by local mass effect and systemic inflammatory responses.

• Vague Abdominal/Flank Pain: Most patients present with dull, continuous back or flank pain that may radiate to the groin or scrotum.
• Renal Insufficiency: Patients may present with uremic symptoms such as nausea, fatigue, pruritus, or metallic taste if the obstruction has led to significant decline in eGFR.
• Systemic Symptoms: Low-grade fever, weight loss, night sweats, and malaise are common, reflecting the underlying inflammatory nature of the disease.
• Vascular Symptoms: Lower extremity edema or claudication may occur if the fibrotic mass interferes with venous drainage or arterial flow.

Nephrological Presentation

Unlike primary glomerulonephritis, RPF primarily causes a post-renal obstructive pattern. However, if the inflammation is systemic, patients might exhibit findings suggestive of nephritic syndrome (e.g., hematuria or hypertension) if the renal vasculature is involved. It is critical to differentiate between acute obstruction (elevated creatinine, hydronephrosis) and chronic damage (small, scarred kidneys).

4. Standard Diagnostic Evaluation & Workup

The diagnostic workup for RPF must prioritize the assessment of renal function and the identification of the underlying etiology.

Imaging Modalities

1. Computed Tomography (CT) with Contrast: The gold standard. It reveals a periaortic mantle of soft tissue that typically spares the ureters from displacement (they are often pulled medially).
2. Magnetic Resonance Imaging (MRI): Useful for assessing the activity of the fibrotic plaque; T2-weighted sequences can help distinguish between active inflammation (high signal) and dense, mature fibrosis (low signal).
3. PET/CT: Increasingly used to assess disease activity and identify occult malignancy.

Laboratory Assays

• Renal Function Panel: Monitoring creatinine and eGFR trends is mandatory.
• Inflammatory Markers: Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are typically elevated and serve as markers for treatment response.
• Immunological Workup: Serum IgG4 levels, ANA, and ANCA to rule out secondary autoimmune causes.

Renal Biopsy Indications

Biopsy of the retroperitoneal mass is usually reserved for cases where malignancy is suspected or if the patient fails to respond to initial immunosuppressive therapy. From a nephrological standpoint, a renal biopsy may be indicated if there is evidence of intrinsic renal disease (e.g., proteinuria, active urinary sediment) that cannot be explained solely by obstruction.

5. Therapeutic Interventions

Treatment follows a dual path: relieving obstruction and suppressing the underlying inflammatory process.

Pharmacotherapy

• Glucocorticoids: The first-line treatment for idiopathic RPF. High-dose prednisone (often starting at 0.5–1.0 mg/kg/day) is used to induce remission.
• Steroid-Sparing Agents: If the patient is steroid-dependent or refractory, agents such as Mycophenolate Mofetil (MMF), Azathioprine, or Tamoxifen (historically used) are employed.
• Biologics: Rituximab is increasingly utilized for IgG4-related RPF, showing significant success in reducing plaque volume and inflammation.

Surgical/Urological Interventions

• Ureteral Stenting: Immediate relief of hydronephrosis is critical to prevent permanent tubular damage and renal failure.
• Ureterolysis: Surgical relocation of the ureters out of the fibrotic plaque, often wrapped in omentum to prevent re-entrapment.
• Nephrostomy Tubes: Used in cases of severe AKI where retrograde stenting is impossible.

KDIGO-Aligned Management

Following KDIGO principles, management focuses on preventing the progression of CKD. This includes strict blood pressure control (ACE inhibitors or ARBs, provided the obstruction is relieved), management of CKD-MBD (bone mineral density), and regular monitoring of eGFR to track recovery post-obstruction.

6. Frequently Asked Questions (FAQ)

1. Is Ormond’s Disease a form of kidney cancer?
   No, it is a non-malignant, fibro-inflammatory condition. However, it can mimic or be triggered by underlying malignancies.
2. How quickly does RPF affect my eGFR?
   The decline in eGFR depends on the severity of the ureteral obstruction. Acute, bilateral obstruction can lead to rapid-onset AKI.
3. Can I recover my kidney function after treatment?
   Yes, if the obstruction is relieved early and tubular atrophy is minimal, renal function often recovers significantly.
4. Why is my doctor checking IgG4 levels?
   IgG4-related disease is a common underlying cause of RPF. Identifying this allows for more targeted therapy, such as Rituximab.
5. What is the role of the nephrologist in my care?
   The nephrologist manages your renal function, monitors electrolyte balance, treats hypertension, and coordinates immunosuppressive therapy.
6. Are there specific dietary restrictions?
   If you are in advanced stages of CKD, you may need to limit potassium, phosphorus, and protein. Always consult your renal dietitian.
7. Is Retroperitoneal Fibrosis hereditary?
   There is no strong evidence that RPF is inherited; it is generally considered an acquired, immune-mediated disorder.
8. Will I need long-term medication?
   Many patients require long-term low-dose immunosuppression to prevent recurrence of the fibrotic plaque.
9. What are the warning signs of a recurrence?
   Recurrence often presents as returning flank pain, unexplained weight loss, or a sudden dip in your eGFR/rise in creatinine.
10. How often should I have follow-up imaging?
    Initially, frequent imaging (every 3–6 months) is required to monitor the size of the fibrotic mass and ensure the ureters remain patent.

Clinical Disclaimer: This guide is for educational purposes only and does not substitute professional medical advice. If you suspect you have symptoms related to retroperitoneal fibrosis, consult a nephrologist or urologist immediately for a formal evaluation.